InspireMD Stock Discussion

$InspireMD(NSPR.US)$ the mesh stint will become FDA approved. When is the question.

$InspireMD(NSPR.US)$ InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

$InspireMD(NSPR.US)$ InspireMD Inc -U.S. Commercial Launch of Cguard™ Prime Carotid Stent System Anticipated in H1 2025, IF Approved

$InspireMD(NSPR.US)$ INSPIREMD INC -STUDY RESULTS TO SUPPORT A PREMARKET APPROVAL (PMA) APPLICATION TO FDA IN H2 2024
Reuters05/28/2024 08:53

$InspireMD(NSPR.US)$ InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 60.38 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $1.511 billion which beat the analyst consensus estimate of $1.384 million by 109.08K percent. This is a 121.85K percent increase over sales of $1.239 million the same period...

$InspireMD(NSPR.US)$ InspireMD Announces Abstract Of One-year Follow-up Results From C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial Accepted For Presentation At LINC 2024
Benzinga· 1 min ago

$InspireMD(NSPR.US)$ InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework
3 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE

$InspireMD(NSPR.US)$ InspireMD Reveals Issuance Of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System
Benzinga· 1 min ago

$InspireMD(NSPR.US)$ Director ROUBIN GARY S purchased 50,000 shares of Common Stocks on Nov 30, 2023 at an average price of $2.5308 for a total value of $126.54K.